(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Recommendations

Info

Trastuzumab + Pertuzumab
Trastuzumab binds to subdomain IV of HER2, continually suppresses HER2 activity and flags cells for destruction by the immune system angiogenesis RAS Sos Grb2 Shc Raf MEK MAPK HER2 mTOR PI3K Cyclin D1 cell cycle control proliferation HER2 p27 PDK1 BAD AKT NFκB ↓ apoptosis GSK3β ↑ survival
Page 1 and 2: Utilizzo dei farmaci nei diversi co
Page 3 and 4: HER2 positive breast cancer “Targ
Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
Page 9 and 10: Antibody-Dependent Cellular Cytotox
Page 11 and 12: Potenziale meccanismo di trastuzuma
Page 13: Malattia adiuvante
Page 17 and 18: DFS: Sequential (Arm B: AC → T
Page 19 and 20: Malattia Neo- adiuvante
Page 21 and 22: Studio NOAH: Event Free Survival ne
Page 23 and 24: Trastuzumab has transformed the pro
Page 25 and 26: Definition of resistance In most tu
Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
Page 29 and 30: Trastuzumab Capecitabine von Minckw
Page 31 and 32: GBG 26/BIG 03-05: main results Cape
Page 33 and 34: Phase III, randomised, controlled s
Page 35 and 36: Lapatinib • Binds to intracellula
Page 37 and 38: Lapatinib may sensitise HER2 positi
Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
Page 41: HER2 dimerization is key to signali
Page 45 and 46: Trastuzumab and pertuzumab may have
Page 47 and 48: Receptor-T-DM1 complex is internali

(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Create successful ePaper yourself

Delete template?

Save as template?